M. Reni et al. / Critical Reviews in Oncology/Hematology 63 (2007) 81–89
89
[67] Imhof HG, Hany M, Wiestler OD, Glanzmann C. Long-term follow-
up in 39 patients with an ependymoma after surgery and irradiation.
Strahlenther Onkol 1992;168:513–9.
[68] Waldron JN, LaperriereNJ, Jaakkimainen L, et al. Spinal cord ependy-
momas: a retrospective analysis of 59 cases. Int J Radiat Oncol Biol
Phys 1993;27:223–9.
[69] Clover LL, Hazuka MB, Kinzie JJ. Spinal cord ependymomas treated
with surgery and radiation therapy. A review of 11 cases. Am J Clin
Oncol 1993;16:350–3.
[70] Schwartz TH, McCormick PC. Intramedullary ependymomas: clin-
ical presentation, surgical treatment strategies and prognosis. J
Neurooncol 2000;47:211–8.
[71] Mork SJ, Loken AC. Ependymoma: a follow-up study of 101 cases.
Cancer 1977;40:907–15.
[72] Perilongo G, Massimino M, Sotti G, et al. Analyses of prognostic fac-
tors in a retrospective review of 92 children with ependymoma: Italian
Pediatric Neuro-oncology Group. Med Pediatr Oncol 1997;29:79–85.
[73] Paulino AC. The local field in infratentorial ependymoma: does the
entire posterior fossa need to be treated? Int J Radiat Oncol Biol Phys
2001;49:757–61.
[74] Donahue B, Steinfeld A. Intracranial ependymoma in the adult
patient: successful treatment with surgery and radiotherapy. J Neu-
rooncol 1998;37:131–3.
[75] Palma L, Celli P, Mariottini A, et al. The importance of surgery in
supratentorial ependymomas. Long-term survival in a series of 23
cases. Childs Nerv Syst 2000;16:170–5.
[76] Davis C, Symon L. Posterior fossa ependymomas in adults. Acta
Neurochir (Wien) 1986;82:115–7.
[77] Karim AB, Afra D, Cornu P, et al. Randomized trial on the efficacy
of radiotherapy for cerebral low-grade glioma in the adult: European
Organization for Research and Treatment of Cancer Study 22845 with
the Medical Research Council study BRO4: an interim analysis. Int J
Radiat Oncol Biol Phys 2002;52:316–24.
[78] Ernestus RI, Wilcke O. Spinal metastases of intracranial ependymo-
mas. Four case reports and review of the literature. Neurosurg Rev
1990;13:147–54.
[79] Packer RJ, Schut L, Siegel KR. Dissemination of primary central ner-
vous system tumors of childhood: incidence and clinical implications.
Prog Exp Tumor Res 1987;30:206–14.
[80] Marks JE, Adler SJ. A comparative study of ependymomas by site of
origin. Int J Radiat Oncol Biol Phys 1982;8:37–43.
[81] Salazar OM, Castro-Vita H, VanHoutte P, et al. Improved survival in
cases of intracranial ependymoma after radiation therapy. Late report
and recommendations. J Neurosurg 1983;59:652–9.
[82] Kim YH, Fayos JV. Intracranial ependymomas. Radiology
1977;124:805–8.
[83] Merchant TE, Zhu Y, Thompson SJ, et al. Preliminary results from
a Phase II trail of conformal radiation therapy for pediatric patients
with localised low-grade astrocytoma and ependymoma. Int J Radiat
Oncol Biol Phys 2002;52:325–32.
[84] Evans AE, Anderson JR, Lefkowitz-Boudreaux IB, Finlay JL.
Adjuvant chemotherapy of childhood posterior fossa ependymoma:
cranio-spinal irradiation with or without adjuvant CCNU, vincristine,
and prednisone: a Childrens Cancer Group study. Med Pediatr Oncol
1996;27:8–14.
[85] Bouffet E, Foreman N. Chemotherapy for intracranial ependymomas.
Childs Nerv Syst 1999;15:563–70.
[86] Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative
chemotherapy and delayed radiation in children less than three years
of age with malignant brain tumors. NEngl J Med 1993;328:1725–31.
[87] Kuhl J, Muller HL, Berthold F, et al. Preradiation chemotherapy of
children and young adults with malignant brain tumors: results of the
German pilot trial HIT’88/’89. Klin Padiatr 1998;210:227–33.
[88] Mason WP, Goldman S, Yates AJ, et al. Survival following inten-
sive chemotherapy with bone marrow reconstitution for children with
recurrent intracranial ependymoma—a report of the Children’s Can-
cer Group. J Neurooncol 1998;37:135–43.
[89] Grill J, Kalifa C, Doz F, et al. A high-dose busulfan-thiotepa com-
bination followed by autologous bone marrow transplantation in
childhood recurrent ependymoma. A phase-II study. Pediatr Neuro-
surg 1996;25:7–12.
[90] Aggarwal R, Yeung D, Kumar P, et al. Efficacy and feasibil-
ity of stereotactic radiosurgery in the primary management of
unfavorable pediatric ependymoma. Radiother Oncol 1997;43:269–
73.
[91] Stafford SL, Pollock BE, Foote RL, et al. Stereotactic radiosurgery
for recurrent ependymoma. Cancer 2000;88:870–5.
[92] Jawahar A, Kondziolka D, Flickinger JC, Lunsford LD. Adju-
vant stereotactic radiosurgery for anaplastic ependymoma. Stereotact
Funct Neurosurg 1999;73:23–30.
[93] Kadota RP, Stewart CF, Horn M, et al. Topotecan for the treat-
ment of recurrent or progressive central nervous system tumors—a
pediatric oncology group phase II study. J Neurooncol 1999;43:
43–7.
[94] Ruda R, Costanza A, Nobile M, et al. Response of ependymo-
mas to chemotherapy with temozolomide. J Neurooncol 2001;
3:66.
[95] Corn BW, Yousem DM, Scott CB, et al. White matter changes are
correlated significantly with radiation dose. Observations from a
randomized dose-escalation trial for malignant glioma (Radiation
Therapy Oncology Group 83-02). Cancer 1994;74:2828–35.
[96] Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral
sequelae of cranial irradiation in adults: a review of radiation-induced
encephalopathy. J Clin Oncol 1994;12:627–42.
[97] Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas:
MR imaging spectrum of radiation therapy- and chemotherapy-
induced necrosis of the brain after treatment. Radiology 2000;217:
377–84.
[98] Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy
and other treatment-related factors on mid-term to long-term cog-
nitive sequelae in low-grade gliomas: a comparative study. Lancet
2002;360:1361–8.
[99] Gregor A, Cull A, Traynor E, et al. Neuropsychometric evaluation of
long-term survivors of adult brain tumours: relationship with tumour
and treatment parameters. Radiother Oncol 1996;41:55–9.
[100] Brandes AA, Pasetto LM, Lumachi F, Monfardini S. Endocrine dys-
functions in patients treated for brain tumors: incidence and guidelines
for management. J Neurooncol 2000;47:85–92.
Biographies
Michele Reni
is Coordinator of the Clinical Research and
Vice Director of the Medical Oncology Unit, San Raffaele
Scientific Institute, Milan, Italy.
Gemma Gatta
is Assistant Researcher in the Unit of Epi-
demiology of Istituto Nazionale Tumori, Milan, Italy. She is
involved in projects with population based cancer registries
on incidence, survival and prevalence.
Elena Mazza
collaborates with Michele Reni in the Clin-
ical Research as Registrar in Medical Oncology Unit, San
Raffaele Scientific Institute, Milan, Italy.
Charles Vecht
(1947) is a neurologist-oncologist at the
Medical Centre The Hague in the The Netherlands, where he
is the coordinator of the Hospital Neuro-oncology Program.
Dr. Vecht’s clinical research focuses mainly on primary brain
tumours with a special interest for epilepsy associated with
cancer.